1. Canada Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Appili Therapeutics Inc Class A

Appili Therapeutics Inc Class A

0.01
CAD
+0.00
(-50.00%)
-0.04EPS
1.99MMarket Cap
Nov 12Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
0.01
- -
0.02
- -
0.01
- -
- -
- -
Basic EPS, GAAP
-0.12
-0.13
-0.16
-0.24
-0.38
-0.08
-0.03
-0.02
-0.03
-0.04
Free Cash Flow per Basic Share
-0.1
-0.1
-0.12
-0.19
-0.29
-0.09
-0.02
0.01
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.15
0.13
0.19
0.2
-0.05
-0.06
-0.09
-0.11
-0.13
-0.14
Tangible Book Value per Share
0.15
0.13
0.19
0.2
-0.05
-0.06
-0.09
-0.11
-0.13
-0.14
Basic Weighted Avg Shares
34
34
34
59
67
114
121
121
124
129
Sales/Revenue/Turnover
- -
- -
- -
- -
1
- -
1
- -
- -
- -
Operating Margin (%)
- -
- -
-2,734.5
- -
-1,698.12
-2,326.86
-261.39
-190
-1,564.89
-1,105.03
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-4
-5
-14
-25
-9
-4
-3
-4
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-2,720.41
- -
-1,806.18
-2,765.9
-456.96
-2,613.12
-1,736.73
-1,294.52
Working Capital
6
5
10
14
2
- -
-10
-13
-17
-18
LT Debt
1
1
1
1
5
8
1
1
1
1
Total Equity
5
4
9
13
-3
-7
-11
-13
-17
-19
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-93.27
-81.66
-132.65
- -
- -
- -
- -
- -
- -

Capital Structure

CAD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
12
12
13
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
128
132
132
Market Capitalization
3
2
2

Working Capital

CAD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
1
2
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
16
19
20
Payables & Accruals
4
6
7
ST Debt
12
12
13
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
20.04%
29.37%
Free Cash Flow
- -
-88.99%
-254.35%
Net Income, GAAP
- -
-3.19%
61.57%
Sales/Revenue/Turnover
- -
- -
143.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.01
-0.01
- -
- -
-0.02
2026
-0.01
-0.01
-0.01
-0.01
-0.03
2027
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Don Cilla
Full Time Employees
7
Sector
Health technology
Industry
Pharmaceuticals: major
Address
#21-1344 Summer Street Halifax NS Canada B3H 0A8
IPO Date
Jun 25, 2019
Website
appilitherapeutics.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Appili Therapeutics Inc. (TSX: APLI) is a biopharmaceutical company focused on acquiring, developing and commercializing novel anti-infective therapies and medical countermeasures targeting unmet needs in infectious diseases and biodefense; its core pipeline includes LIKMEZ (ATI-1501), an FDA-approved taste-masked oral suspension of metronidazole for anaerobic bacterial, protozoal and parasitic infections commercialized since late 2023 with newly granted patents in 2025; ATI-1801, a topical paromomycin formulation in Phase III for cutaneous leishmaniasis and disfiguring skin infections; ATI-1701, a live-attenuated vaccine candidate in preclinical to clinical stages for tularemia (Francisella tularensis), a serious biothreat; and emerging programs such as a broad-spectrum antiviral host-directed treatment and the VXV-01 fungal vaccine developed with partner Vitalex Biosciences under a NIAID contract valued at up to US$40 million awarded in October 2025. The company, founded in 2015 and headquartered in Halifax, Nova Scotia, Canada, with a U.S. office in Frederick, Maryland, operates primarily in North America while pursuing global biodefense opportunities through collaborations with U.S. government agencies including the Department of Defense, Medical CBRN Defense Consortium, and NIH; it has secured over US$66 million in non-dilutive government funding to date, including recent submissions for up to US$117.5 million in federal proposals in March 2025 and membership in key consortia for advancing countermeasures. Recent developments encompass the formal termination of a proposed going-private arrangement with Aditxt Inc. in May 2025, extension of related timelines, strengthened biodefense positioning via publications on ATI-1701 efficacy and tularemia response in 2025, ongoing regulatory engagements for ATI-1801, and pursuit of Priority Review Vouchers for expedited approvals.